Sana Biotechnology (SANA) Other Accumulated Expenses (2020 - 2026)

Sana Biotechnology has reported Other Accumulated Expenses for 7 years, with the latest figure at $1.8 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 16.02% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 16.02% YoY) and the FY2025 annual result came in at $1.6 million, down 9.06% from the prior year.
• Other Accumulated Expenses advanced to $1.8 million in Q1 2026 per SANA's latest filing, from $1.6 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $3.7 million in Q3 2024 and troughed at $1.3 million in Q3 2025.
• A 5-year average of $2.3 million and a median of $2.1 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses surged 78.9% in 2024, then plunged 64.08% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $2.9 million in 2022, then decreased by 6.42% to $2.7 million in 2023, then plunged by 34.6% to $1.8 million in 2024, then retreated by 9.06% to $1.6 million in 2025, then increased by 11.72% to $1.8 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.8 million, $1.6 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.